Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
Study Identifier:
ALXN1210-COV-305
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
EU CT ID:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Available Documents
Study Details
Medical Condition
- Unmapped
- Lungs & Respiratory - Other
Study Drug
- Biological: Ravulizumab
Date
May 2020 - Feb 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
- Lungs & Respiratory - Other
Study Drug
- Biological: Ravulizumab
Date
May 2020 - Feb 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute respiratory distress syndrome. Participants were randomly assigned to receive ravulizumab in addition to best supportive care (BSC) (2/3 of the participants) or BSC alone (1/3 of the participants). BSC consisted of medical treatment and/or medical interventions per routine hospital practice.
Trial Locations
Location
Status
Location
Central Arkansas Veterans Healthcare System
Little Rock, Arkansas, United States, 72205
Status
N/A
Location
LAC/USC Health Center
Los Angeles, California, United States, 90033
Status
N/A
Location
UC Irvine Medical Center
Orange, California, United States, 92868
Status
N/A
Location
MedStar Georgetown University Hospital
Washington, District of Columbia, United States, 20007
Status
N/A
Location
University of Florida
Jacksonville, Florida, United States, 32209
Status
N/A
Location
Mayo Clinic Florida
Jacksonville, Florida, United States, 32224
Status
N/A
Go to page